NEWS

29/05/2008

Directors Share Purchase

Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, today received notification (subsequent to the release of the Company’s Interim Results) that the following Directors purchased shares in Renovo:

Director	Ordinary shares purchased	Price per share	Ordinary shares held following purchase	Percentage of issued share capital
Rodger Pannone Chairman	35,000	27.00p	53,750	0.03%
Prof Mark Ferguson CEO and co-founder	185,185	27.00p	8,032,673	4.24%
Dr Sharon O' Kane CSO and co-founder	111,111	27.00p	4,729,351	2.50%
Andrew Kay Commercial Director	74,074	27.00p	74,074	0.04%
Dr Barrie Thorp Non-executive Director	37,000	27.00p	44,185	0.02%
Dr David Ebsworth Non-executive Director	37,000	27.14p	57,000	0.03%
Lord Leslie Turnberg Non-executive Director	35,850	27.72p	55,850	0.03%
John Goddard Non-executive Director	37,000	27.75p	37,000	0.02%

For further information please contact:

Renovo
Simon Bielecki, Vice President, Communications
Tel: +44 (0) 7810 157649

Buchanan Communications
Mary-Jane Johnson / Tim Anderson / Lisa Baderoon
Tel: +44 (0) 20 7466 5000

About Renovo Group plc

Renovo is a biopharmaceutical product company and a leader in the discovery and development of drugs to improve the appearance of scars and enhance wound healing.

Renovo has a portfolio of drugs which exploit different novel mechanisms of action to reduce scarring at multiple body sites and accelerate healing. Juvista, Renovo’s lead drug for the reduction of scarring in the skin, has been generally well tolerated by around 1,500 human subjects and has provided statistically significant efficacy data in seven Phase 2 double blind, placebo controlled efficacy trials.

Renovo announced in June 2007 that it had signed an exclusive licensing agreement with Shire plc to develop and commercialise Juvista. The agreement covers every country in the world except the European Union, the rights to which have been retained by Renovo. Under the terms of the deal Renovo has already received an initial upfront payment of US$75 million and an equity investment of US$50 million. Contingent on the successful development and commercialisation of Juvista Renovo will be eligible for further payments of up to $700 million together with escalating royalties on sales.

Zesteem, Renovo’s lead drug for the acceleration of wound healing in the skin is currently being investigated in a Phase 3 clinical trial. Prevascar reported statistically significant Phase 2 efficacy data for the reduction of scarring in the skin in April 2007 and is also being investigated for enhancing regeneration of peripheral nerves following injury or trauma. Juvidex is in a Phase 2 trial for the acceleration of healing in the skin. In addition Renovo has an extensive preclinical pipeline.

For further information on Renovo please visit: www.renovo.com